Welcome to our dedicated page for Alvotech news (Ticker: ALVO), a resource for investors and traders seeking the latest updates and insights on Alvotech stock.
Alvotech (NASDAQ: ALVO) is a biotechnology company dedicated exclusively to biosimilars, and its news flow reflects the progress of a global biosimilar platform. Company updates frequently cover regulatory milestones, such as marketing authorizations in the European Economic Area, the United Kingdom and Japan for products referencing Prolia and Xgeva (denosumab), Simponi (golimumab) and Eylea (aflibercept). Press releases also highlight clinical and regulatory developments for new candidates, including submissions to agencies like the European Medicines Agency and the U.S. Food and Drug Administration.
Investors following ALVO news can expect regular announcements on product approvals, pipeline progress and legal or regulatory outcomes. Recent communications have described European Commission approval of AVT03, a biosimilar to Prolia and Xgeva, positive opinions from EMA committees for AVT03 and AVT05, and a settlement and license agreement enabling a future U.S. launch of AVT06, a proposed biosimilar to Eylea, subject to FDA approval. Other items include court decisions related to manufacturing activities for AVT06 and updates on applications for additional candidates such as AVT23.
Alvotech’s news flow also includes capital markets and financing transactions, such as senior unsecured convertible bond offerings and a senior term loan facility, which the company states are intended to support its research and development pipeline, manufacturing capacity and global product launches. Earnings-related press releases and business updates provide guidance ranges for revenues and adjusted EBITDA, along with commentary on order books, launch timing and investment programs.
Corporate governance and leadership changes are another recurring theme. For example, Alvotech has announced a planned CEO succession in which the founder will remain as Executive Chairman while a new Chief Executive Officer takes over day-to-day leadership. For users tracking ALVO, this news page offers a centralized view of regulatory, financial and strategic developments affecting the company’s biosimilar portfolio and global partnerships.
Teva Pharmaceuticals and Alvotech have announced the U.S. launch of SIMLANDI (adalimumab-ryvk) injection, an interchangeable biosimilar to Humira. This product is the first high-concentration, citrate-free biosimilar approved by the FDA. SIMLANDI is indicated for treating multiple conditions including adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, and more. The launch aims to provide cost savings and improved access to patients and healthcare providers. The companies entered a strategic partnership in 2020, focusing on commercializing biosimilars in the U.S. market. Teva handles commercialization, while Alvotech manages development and manufacturing.
The Annual General Meeting of Alvotech S.A. is scheduled for June 7, 2024, at 09.00 a.m. CEST. It will be held at Arendt & Medernach S.A., located at 41A, Avenue John F. Kennedy, L-1855 Luxembourg, Grand Duchy of Luxembourg.
The agenda and related materials for the meeting are available on the Alvotech website. This meeting is important as it could address key decisions impacting the financial and operational strategies of the company. Investors can find further details and updates through the provided investor relations contact.
UCLOUDLINK GROUP announced their unaudited Q1 2024 financial results, showcasing a strategic partnership between Alvotech and Teva Pharmaceuticals. Alvotech will manufacture a high-concentration interchangeable biosimilar to Humira for Quallent Pharmaceuticals. This biosimilar, approved by the FDA in Feb 2024, will be distributed under Quallent's private label. The biosimilar aims to treat multiple conditions, including rheumatoid arthritis and Crohn's disease, and represents nearly 88% of U.S. prescriptions for adalimumab. The collaboration aims to make affordable biologics widely accessible.
Alvotech, a global biotech company, will release its first quarter 2024 financial results on May 21, 2024, followed by a conference call on May 22, 2024, to discuss the results and recent business highlights. The webcast of the conference call will be available for replay for 90 days.
Alvotech, a global biotech company, will be participating in the BofA Securities Healthcare Conference 2024 in Las Vegas, NV on May 14-15, 2024. The company's management team will be engaging in one-on-one meetings with investors during the event.
Alvotech has entered into a U.S. commercialization agreement with Quallent Pharmaceuticals to manufacture a high-concentration interchangeable biosimilar to Humira® (adalimumab). This agreement is part of Alvotech's strategic partnership with Teva Pharmaceuticals for U.S. commercialization. The biosimilar will be distributed under Quallent's private label, aiming to provide eligible patients with a copay assistance program. The FDA approved Alvotech's biosimilar as the first high-concentration, citrate-free biosimilar to Humira® granted interchangeability status, with nearly 88% of U.S. adalimumab prescriptions for high-concentration presentations.
Alvotech and Teva's partnership has already yielded two approved critical biosimilars, with more in development. Alvotech focuses on development and manufacturing, while Teva handles U.S. commercialization. Teva expects to launch Alvotech's high concentration interchangeable biosimilar to Humira® imminently.
Summary not available.
Summary not available.
Summary not available.
Summary not available.